Citations

Clear

3030 citation(s) found for "Susan, M".

Association of New-Onset Atrial Fibrillation After Noncardiac Surgery With Subsequent Stroke and Transient Ischemic Attack
Siontis, Konstantinos C. , Weston, Susan A., Jiang, Ruoxiang , Kashou, Anthony H. , Roger, Véronique L. , Chamberlain, Alanna M. , Chamberlain, Alanna M , Gersh, Bernard J. , Noseworthy, Peter A.

Mayo Clinic

JAMA | September 1, 2020 | Volume: 324 | Issue: 9 | Pages: 871

10.1001/jama.2020.12518 | PMID 32870297 Get It

Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors
Chiorean, E. Gabriela , Perkins, Susan M. , Younger, Anne, Funke, Jennifer M., Shahda, Safi, Hahn, Noah M. , Sandrasegaran, Kumar , Jones, David , Skaar, Todd C. , Schneider, Bryan P. , Sweeney, Christopher J. , Matei, Daniela E , Sweeney, Christopher , Strother, Robert Matthew , Jones, David R., Matei, Daniela

Mayo Clinic

Molecular Cancer Therapeutics | August 26, 2020 | Volume: 19 | Issue: 10 | Pages: 2155-2162

10.1158/1535-7163.mct-20-0277 | PMID 32847973 Get It

Abstract VEGF blockade does not uniformly result in clinical benefit. We evaluated safety, dose-limiting toxicities (DLT), recommended phase II dose (RP2D), antitumor efficacy, and exploratory biomarkers including pharmacogenomics and pharmacokinetics with sorafenib, bevacizumab, and paclitaxel in patients with refractory cancers. The study had a “3 + 3” design, using paclitaxel 80 mg/m2 every week for 3 weeks, in every 4 week cycles, bevacizumab 5 mg/kg every 2 weeks, and sorafenib 200 or 400 mg twice a day, 5 or 7 days/week (5/7, 7/7). The MTD cohort was expanded. Twenty-seven patients enrolled in 3 cohorts: sorafenib 200 mg twice a day 5/7, 200 mg twice a day 7/7, and 400 mg twice a day 5/7. DLTs were grade 3 neutropenia >7 days (cohort 1, 1), grade 3 hypertension (cohort 2, 1), grade 3 hand–foot skin reaction (HFSR; cohort 3, 2). MTD was sorafenib 200 mg twice a day 7/7. Six DLTs occurred in cohort 2 expansion: grade 3 HFSR (2), grade 2 HFSR with sorafenib delay >7 days (2), grade 4 cerebrovascular accident (1), grade 3 neutropenia >7 days (1). RP2D was sorafenib 200 mg twice a day 5/7. Most patients (62%) dose reduced sorafenib to 200 mg daily 5/7 after a median 3 (range, 2–17) cycles. Response rates were 48% overall (27) and 64% for ovarian cancers (14). VEGF-A-1154AA and -7TT recessive homozygous genotypes conferred worse overall survival versus alternative genotypes (7 vs. 22 months). Intermittent, low-dose sorafenib (200 mg twice a day 5/7) combined with bevacizumab and paclitaxel was tolerable and had high antitumor efficacy in patients with refractory cancer (NCT00572078).
Salivary and lacrimal dysfunction after radioactive iodine for differentiated thyroid cancer: American Head and Neck Society Endocrine Surgery Section and Salivary Gland Section joint multidisciplinary clinical consensus statement of otolaryngology, ophtha
Singer, Michael C. , Marchal, Francis, Bernet, Vic, Boucai, Laura , Buchholzer, Samanta , Burkey, Brian B., Eisele, David W. , Faure, Fréderic , Freitag, Suzanne K. , Gillespie, M. Boyd , Harrell, R. Mack, Hartl, Dana M. , Haymart, Megan R. , Leffert, Jonathan, Mandel, Susan J., Miller, Barbra S. , Pearce, Elizabeth N. , Rahmati, Rahmatullah, Ryan, William R. , Schaitkin, Barry M., Schlumberger, Martin, Stack, Brendan C. , Nostrand, Doug Van, Wong, Ka Kit , Stack, Brendan C , Pearce, Elizabeth N , Angelos, Peter , Bernet, Victor , Buchholzer, Samanta , Erkul, Evren , Morris, John, Nostrand, Douglas Van , Randolph, Gregory William

Mayo Clinic

Head & Neck | August 26, 2020 | Volume: 42 | Issue: 11 | Pages: 3446-3459

10.1002/hed.26417 | PMID 32812307 Get It

AbstractBackgroundPostoperative radioactive iodine (RAI) administration is widely utilized in patients with differentiated thyroid cancer. While beneficial in select patients, it is critical to recognize the potential negative sequelae of this treatment. The prevention, diagnosis, and management of the salivary and lacrimal complications of RAI exposure are addressed in this consensus statement.MethodsA multidisciplinary panel of experts was convened under the auspices of the American Head and Neck Society Endocrine Surgery and Salivary Gland Sections. Following a comprehensive literature review to assess the current best evidence, this group developed six relevant consensus recommendations.ResultsConsensus recommendations on RAI were made in the areas of patient assessment, optimal utilization, complication prevention, and complication management.ConclusionSalivary and lacrimal complications secondary to RAI exposure are common and need to be weighed when considering its use. The recommendations included in this statement provide direction for approaches to minimize and manage these complications.
Phase I trial and pharmacokinetic study of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with refractory solid tumors: A Children's Oncology Group Phase I Consortium study
Wagner, Lars M. , Ames, Matthew M. , Nelson, Marybeth, Ingle, A. M., Blaney, Susan M. , Adamson, P. C., Perentesis, John P. , Reid, Joel M. , Safgren, Stephanie L. , Nelson, M. D.

Mayo Clinic

Journal of Clinical Oncology | August 25, 2020 | Volume: 27 | Issue: 15_suppl | Pages: 10017-10017

10.1200/jco.2009.27.15_suppl.10017 Get It

10017 Background: In preclinical models, temozolomide (TMZ) and vincristine (VCR) are synergistic with irinotecan (IRN). We sought to determine the dose limiting toxicities (DLTs) and maximum tolerated dose (MTD) of orally administered IRN given on two different schedules together with TMZ and VCR in children with refractory solid tumors, using cefixime to reduce IRN-associated diarrhea. Methods: Schedule A: Oral IRN daily for 5 days for 2 weeks (dx5x2), with VCR 1.5 mg/m2 on days 1 and 8 and TMZ 100 mg/m2 on days 1 - 5. Schedule B: Oral IRN daily for 5 days for 1 week (dx5x1) with VCR 1.5 mg/m2 on day 1 and TMZ 100 - 150 mg/m2 on days 1 - 5. Courses were repeated every 3 weeks. A standard cohorts of 3 + 3 design was used. Results: On Schedule A, 18 evaluable patients (median age 15 yrs, range 3 - 21) received 55 courses. At IRN 50 mg/m2/day, 4/12 pts had DLT (hepatotoxicity, abdominal pain, anorexia, hypokalemia, and thrombocytopenia). The oral IRN MTD on this dx5x2 schedule was 35 mg/m2/d (1/6 pts with DLT of hypoalbuminemia). On Schedule B, 18 evaluable patients (median age 9 yrs, range 3–21) received 71 courses of oral IRN 70 - 90 mg/m2/d x 5 with TMZ 100 - 150 mg/m2/d x 5. At oral IRN 90 mg/m2/d with TMZ 150 mg/m2/d, 0/6 pts had DLT, and no Grade 4 toxicities were seen. No further doses were explored. First-course and cumulative toxicity appeared worse with Schedule A, including 3 patients with responding or stable tumors who withdrew due to fatigue, nausea, and weight loss. UGT1A1*28genotype did not correlate with DLT. At the oral IRN MTD of 90 mg/m2/d, the median SN-38 AUCinf was 72 ng/ml*h. One patient with osteosarcoma had a confirmed partial response. Unconfirmed complete and partial responses were seen in 2 Ewing sarcoma patients. Eight additional patients received > 6 courses, including 2 each with neuroblastoma and medulloblastoma. Conclusions: The dx5x1 schedule of VOIT was well tolerated, with SN-38 exposures similar to those achieved with intravenous IRN. Activity on this and prior studies suggests a potential role for VOIT in sarcoma patients. No significant financial relationships to disclose.
First analysis of an international pediatric melanoma and atypical melanocytic neoplasm database
Averbook, Bruce J., Jukic, D.M., Delman, Keith A. , Pittelkow, Mark R. , Rao, Jia‐Sheng , Panneerselvam, A., Zager, Jonathan S. , Sabel, Michael S. , Swetter, Susan M. , Kirkwood, John M.

Mayo Clinic

Journal of Clinical Oncology | August 25, 2020 | Volume: 27 | Issue: 15_suppl | Pages: 9013-9013

10.1200/jco.2009.27.15_suppl.9013 Get It

9013 Background: Pediatric melanoma (PM) care has been extrapolated from adult melanoma data. PM and atypical melanocytic neoplasms (AMNs) appear to have different biology. An international database (DB) was developed to clarify their behavior. Methods: IRB approval was obtained at 12 institutions. An SQL-DB was developed for web entry of de-identified demographic and pathologic data for PM and AMN patients (pts) < 21yr through an honest broker system at the University of Pittsburgh. Institutions retained a key of pts entered with assigned numbers for quality assurance and updates. Statistical analysis used Kaplan-Meier survival curves, univariate linear trends and log rank tests. In situ melanoma was excluded from PM survival analysis. Results: 828 pts were registered as of 31 Oct 2008 (ages 11mo-23; median 15yr). 34 pts 21–23yr entered were left in the DB for statistical comparison. Diagnosis years ranged from 1936–2008. 455 pts had complete follow-up. Too few AMN pts had complete follow-up for analysis (18/208). After excluding 32 in situ and 40 with other incomplete data, 365 PM out of 415 total PM were evaluable for OS and 351 for DFS (Stage IV removed). Mean/median age for evaluable PM pts was 16.44/17-yrs (range 1–21yr). 591 pts were age 10–20 while 203 were < 10. Sentinel lymph node (SLN) biopsy showed spread in 30.1 % PM pts (compared to 50% [4/8] of AMN SLN pts). 10-yr PM OS was 80.6%, and pts 0–10 yr had 100% 10-yr OS compared to 69.6% for pts age 10–15 and 79.49% for age 15–20 (p= 0.1473). OS did not differ significantly by gender. Stage predicted OS (p<0.0001). 10-yr OS was 94.13% for Stage I (n=174), 79.62% for stage II (n=67) & 77.14% for stage III (n=75). Thickness affected 10-yr OS: 0–1mm=97% (n=147), 1.1–2mm 70% (n=84), 2.01–4mm 78% (n=71) & >4mm 81% (n=25), p= 0.0099. Survival was similar for pts with PM > 1mm of the several T stage groupings. Ulceration adversely affected OS (p=0.022). Mitosis, defined as present/absent did not alter survival. Nodal metastasis correlated with worse OS (p= 0.170). Conclusions: Stage, thickness, ulceration, and nodal status are significant predictors of OS for PM. Further study will focus on multivariable analysis of PM and AMNs after updating pts, increasing accrual, and cleaning data. No significant financial relationships to disclose.
Functional assessment of performance status in patients with myelofibrosis (MF): Utility and feasibility of the 6-minute walk test (6MWT)
Kantarjian, H., Tefferi, Ayalew , Pardanani, Animesh , Erickson‐Viitanen, Susan, Thomas, Deborah A. , Mesa, Ruben A. , Cheville, Andrea , Levy, R., Cortes, Jörge E. , Borthakur, Gautam , Verstovšek, Srđan

Mayo Clinic

Journal of Clinical Oncology | August 25, 2020 | Volume: 27 | Issue: 15_suppl | Pages: 7083-7083

10.1200/jco.2009.27.15_suppl.7083 Get It

7083 Background: Patients with Myelofibrosis (MF) suffer from significant fatigue, constitutional symptoms and splenomegaly (Mesa et. al. Cancer 2007) not improved by current therapy. The 6MWT measures functional status in cardio-pulmonary clinical trials. We undertook a prospective feasibility study of the 6MWT in MF patients for use in therapeutic clinical trials. Methods: MF patients (able to walk, normal vitals, not on a JAK2 inhibitor) were eligible. Baseline features and the MF symptom assessment form (MFSAF: Mesa et. al. Blood 2008) was administered. The 6MWT was administered in standardized fashion (American Thoracic Society: observed laps of a 30 - 35 meter long course, indoors, level, without encouragement), and then repeated for further validation. Results: Safety of the 6MWT: Fifty five MF patients were enrolled with only 2 patients (3%) stopping the 6MWT early secondary to fatigue. There were no adverse events attributable to undergoing the 6MWT in test subjects. Results of the 6MWT: Current results of our ongoing study demonstrate compared to age matched healthy volunteer controls, males with MF walk approximately 90 meters less and females with MF walk approximately 60 meters less (Table). Correlation of 6MWT Results to Patient Reported Symptoms (MFSAF): Results from the MFSAF demonstrated the fatigue (as assessed by the brief fatigue inventory (Medoza et. al. Cancer 1999) embedded in the MFSAF) showed patients with a higher BFI (i.e., more fatigued) had more impairment in the 6MWT than those with low BFI scores. Symptomatic burden as assessed by the MFSAF were typical for MF, correlation of individual symptom severity with 6MWT will require a larger trial for adequate power. Conclusions: The 6MWT can be safely performed in un-selected MF patients, and demonstrates a functional deficit compared to published controls. Validation of the ability of the 6MWT to measure functional improvements in MF patients as a response to novel therapy trials is planned. [Table: see text] No significant financial relationships to disclose.
Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters Using the Modified RAND/UCLA Delphi Process
Iyer, Renuka , Acquisto, Susan, Choti, Michael A., Hong, Theodore S. , Kis, Béla , Mead, Peter A., Parikh, Neehar D. , Roberts, Lewis R. , Siegel, Richard S., Whisenant, Jonathan, Cherepanov, Dasha , Broder, Michael S. , Valle, Juan W. , Valle, Juan W , Roberts, Lewis R , Parikh, Neehar D , Bridgewater, John , Roberts, Rebecca, Salem, Riad , Sicklick, Jason Keith

Mayo Clinic

Cancers | August 21, 2020 | Volume: 12 | Issue: 9 | Pages: 2375

10.3390/cancers12092375 | PMID 32825784 Get It

Background: Patients with cholangiocarcinoma often have indwelling biliary stents or catheters which are prone to obstructions and/or infections; studies show that 20–40% present with fever and/or jaundice requiring urgent treatment in the outpatient setting for which there are no uniform guidelines. The goal was to develop an expert panel consensus on this topic using the modified RAND/UCLA Delphi process to rate treatment appropriateness. Methods: Thirteen expert physicians from relevant specialties, geography, and practice settings were recruited for the panel. Patient scenarios were developed and panelists rated the therapies before and after a face-to-face discussion. The appropriateness of various therapies was rated on a scale from 1–9 and classified as appropriate, inappropriate, or uncertain. Scenarios with greater than 2 (>2) ratings of 1–3 (inappropriate) and greater than 2 (>2) ratings of 7–9 (appropriate) were considered to have disagreement and were not assigned an appropriateness rating. Results: Panelists were from all US regions and the UK (8%) and had practiced for a mean 16.5 years (4–33 years). Panelists rated 480 scenarios before the meeting and re-rated 288 of the clinical scenarios after the meeting. The panelists agreed that ongoing treatment with chemotherapy did not influence decision-making and, therefore, 192 scenarios were excluded from the final list. Disagreement decreased from 37.5% before to 10.4% after the meeting. Consensus on stent/tube manipulation and inpatient antibiotic therapy was obtained and summarized in patients as “appropriate” or “maybe appropriate” based on a patient’s bilirubin level at presentation. Conclusions: The Delphi process produced consensus guidelines to fill an unmet need in the urgent management of ascending cholangitis in patients with cholangiocarcinoma.
Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers
Wenz, Brandon M., Kulkarni, Abha , Wubbenhorst, Bradley , D’Andrea, Kurt , Weathers, Benita , Goodman, Noah, Lilyquist, Jenna , Slavin, Thomas P., Ravichandran, Vignesh , Hu, Chunling , Peterlongo, Paolo , Ford, James M. , Shah, Payal D. , Bradbury, Angela R. , Offit, Kenneth , Weitzel, Jeffrey N. , Nathanson, Katherine L. , Hart, Steven N. , Peterlongo, Paolo , Weitzel, Jeffrey N , Hu, Chunling , Nathanson, Katherine L , Ravichandran, Vignesh , Maxwell, Kara N. , Vijai, Joseph , Schrader, Kasmintan A. , Thomas, Tinu , Robson, Mark E. , Bonanni, Bernardo , Garber, Judy E. , Neuhausen, Susan L. , DeMichele, Angela , Couch, Fergus J. , Domchek, Susan M.

Mayo Clinic

JCO Precision Oncology | August 19, 2020 | Volume: No volume available | Issue: 4 | Pages: 916-925

10.1200/po.19.00301 | PMID 32954205 Get It

PURPOSE Women with breast cancer have a 4%-16% lifetime risk of a second primary cancer. Whether mutations in genes other than BRCA1/2 are enriched in patients with breast and another primary cancer over those with a single breast cancer (S-BC) is unknown. PATIENTS AND METHODS We identified pathogenic germline mutations in 17 cancer susceptibility genes in patients with BRCA1/2-negative breast cancer in 2 different cohorts: cohort 1, high-risk breast cancer program (multiple primary breast cancer [MP-BC], n = 551; S-BC, n = 449) and cohort 2, familial breast cancer research study (MP-BC, n = 340; S-BC, n = 1,464). Mutation rates in these 2 cohorts were compared with a control data set (Exome Aggregation Consortium [ExAC]). RESULTS Overall, pathogenic mutation rates for autosomal, dominantly inherited genes were higher in patients with MP-BC versus S-BC in both cohorts (8.5% v 4.9% [ P = .02] and 7.1% v 4.2% [ P = .03]). There were differences in individual gene mutation rates between cohorts. In both cohorts, younger age at first breast cancer was associated with higher mutation rates; the age of non–breast cancers was unrelated to mutation rate. TP53 and MSH6 mutations were significantly enriched in patients with MP-BC but not S-BC, whereas ATM and PALB2 mutations were significantly enriched in both groups compared with ExAC. CONCLUSION Mutation rates are at least 7% in all patients with BRCA1/2 mutation–negative MP-BC, regardless of age at diagnosis of breast cancer, with mutation rates up to 25% in patients with a first breast cancer diagnosed at age < 30 years. Our results suggest that all patients with breast cancer with a second primary cancer, regardless of age of onset, should undergo multigene panel testing.
Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles
Orme, Jacob J. , Enninga, Elizabeth Ann L. , Lucien-Matteoni, Fabrice, Dale, Heather, Burgstaler, Edwin A. , Harrington, Susan M. , Ball, Matthew K. , Mansfield, Aaron S. , Block, M.S., Yan, Yiyi , Dronca, Roxana , Burgstaler, Edwin, Block, Mathew S, Dronca, Roxana S., Mansfield, Aaron S , Enninga, Elizabeth Ann L , Dale, Heather, Park, Sean S. , Markovic, Svetomir N. , Dong, Haidong , Winters, Jeffrey L.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | August 18, 2020 | Volume: 8 | Issue: 2 | Pages: e001113

10.1136/jitc-2020-001113 | PMID 32817395 Get It

Background Trans-acting programmed death-ligand 1 (PD-L1) derives from malignant cells in three known forms. High levels of secreted splice variant PD-L1 (sPD-L1), ADAM10/ADAM17-shed sPD-L1, and PD-L1-positive extracellular vesicles (evPD-L1) each predict poor prognosis and limited response to PD-(L)1 checkpoint inhibitors in cancer. To our knowledge, no clinical intervention has reduced any of these circulating forms of extracellular PD-L1. Here, we explore therapeutic plasma exchange (TPE) as a treatment to reduce circulating extracellular PD-L1. Results In patients with melanoma, sPD-L1 levels above 0.277 ng/mL predicted inferior overall survival. In patients undergoing TPE for non-malignant indications, each TPE session removed a mean 70.8% sPD-L1 and 73.1% evPD-L1 detectable in plasma. TPE also reduced total and ADAM10-positive extracellular vesicles. Conclusion Here, we report the first known clinical intervention to remove either sPD-L1 or evPD-L1 from plasma in vivo. TPE reduces plasma sPD-L1 and evPD-L1 in vivo and may have a role in treatment with immunotherapy. TPE may also prove useful in patients with other extracellular vesicle-related conditions.
Training and education of pediatric radiation oncologists: A survey from the 2019 Pediatric Radiation Oncology Society meeting
Paulino, Arnold C. , Dieckmann, Karin , Mahajan, Anita , Janssens, Geert O. , Halperin, Edward C. , Parkes, Jeannette , Wolden, Suzanne L. , Seiersen, Klaus , Awrey, Susan, Dieter‐Kortmann, Rolf, Marcus, Karen J. , Halperin, Edward C , Parkes, Jeannette , Wolden, Suzanne , Paulino, Arnold C , Esiashvili, Natia , Carrié, C.

Mayo Clinic

Pediatric Blood & Cancer | August 13, 2020 | Volume: 67 | Issue: 10 | Pages: No page available

10.1002/pbc.28619 | PMID 32790118 Get It

AbstractTo examine the educational background, clinical practice, and preferences regarding continuing medical education (CME) among radiation oncologists who attended the 2019 meeting of the Pediatric Radiation Oncology Society (PROS), a survey consisting of 20 questions was distributed asking for demographic and educational background, clinical practice, and preferences regarding pediatric radiation oncology CME. Of 188 participants, 130 (69.2%) returned the questionnaire. More than 80% reported access to CT simulation, three‐dimensional radiotherapy, and general anesthesia while <30% had access to intraoperative radiotherapy, proton, and heavy particle therapy. After residency, 12.1% did further training in pediatric radiation oncology. When asked about further training in pediatrics after residency, 88.8% answered that there should be a formal training program beyond residency in order to treat children. More than 75% acquired knowledge in pediatric radiation oncology through journals, books, live meetings, and tumor boards. The results of this survey may help Pediatric Radiation Oncology Society (PROS) in creating guidelines and recommendations for improvement in pediatric radiation oncology training and practice support as well as the development of CME activities most likely to benefit practitioners.